PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced its financial results for the third quarter and first nine months of 2007. The Company reported net revenue of $62.2 million for third quarter and $185.2 million for the first nine months of 2007. The Company reported a net loss in the third quarter resulting primarily from non-recurring charges related to the July 2, 2007 termination of its distribution arrangements with Nycomed and the reacquisition of all development, commercial and distribution rights held by Nycomed for Angiox(R) (bivalirudin) in Europe.
